246 related articles for article (PubMed ID: 34303799)
21. Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome.
Kang JY; Chadchankar J; Vien TN; Mighdoll MI; Hyde TM; Mather RJ; Deeb TZ; Pangalos MN; Brandon NJ; Dunlop J; Moss SJ
J Biol Chem; 2017 Apr; 292(16):6621-6632. PubMed ID: 28213518
[TBL] [Abstract][Full Text] [Related]
22. Genetic upregulation of BK channel activity normalizes multiple synaptic and circuit defects in a mouse model of fragile X syndrome.
Deng PY; Klyachko VA
J Physiol; 2016 Jan; 594(1):83-97. PubMed ID: 26427907
[TBL] [Abstract][Full Text] [Related]
23. Hyperexcitability in the olfactory bulb and impaired fine odor discrimination in the
Kuruppath P; Xue L; Pouille F; Jones ST; Schoppa NE
bioRxiv; 2023 Apr; ():. PubMed ID: 37090519
[TBL] [Abstract][Full Text] [Related]
24. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
[TBL] [Abstract][Full Text] [Related]
25. Altered structural and functional synaptic plasticity with motor skill learning in a mouse model of fragile X syndrome.
Padmashri R; Reiner BC; Suresh A; Spartz E; Dunaevsky A
J Neurosci; 2013 Dec; 33(50):19715-23. PubMed ID: 24336735
[TBL] [Abstract][Full Text] [Related]
26. BDNF in fragile X syndrome.
Castrén ML; Castrén E
Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
[TBL] [Abstract][Full Text] [Related]
27. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.
Osterweil EK; Krueger DD; Reinhold K; Bear MF
J Neurosci; 2010 Nov; 30(46):15616-27. PubMed ID: 21084617
[TBL] [Abstract][Full Text] [Related]
28. mGluR7 allosteric modulator AMN082 corrects protein synthesis and pathological phenotypes in FXS.
Kumar V; Lee KY; Acharya A; Babik MS; Christian-Hinman CA; Rhodes JS; Tsai NP
EMBO Mol Med; 2024 Mar; 16(3):506-522. PubMed ID: 38374465
[TBL] [Abstract][Full Text] [Related]
29. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice.
Chatterjee M; Kurup PK; Lundbye CJ; Hugger Toft AK; Kwon J; Benedict J; Kamceva M; Banke TG; Lombroso PJ
Neuropharmacology; 2018 Jan; 128():43-53. PubMed ID: 28943283
[TBL] [Abstract][Full Text] [Related]
30. Agmatine relieves behavioral impairments in Fragile X mice model.
Jeon SJ; Kwon H; Bae HJ; Gonzales EL; Kim J; Chung HJ; Kim DH; Ryu JH; Shin CY
Neuropharmacology; 2022 Nov; 219():109234. PubMed ID: 36057317
[TBL] [Abstract][Full Text] [Related]
31. Impaired inhibitory control of cortical synchronization in fragile X syndrome.
Paluszkiewicz SM; Olmos-Serrano JL; Corbin JG; Huntsman MM
J Neurophysiol; 2011 Nov; 106(5):2264-72. PubMed ID: 21795626
[TBL] [Abstract][Full Text] [Related]
32. Genetic reduction of MMP-9 in the Fmr1 KO mouse partially rescues prepulse inhibition of acoustic startle response.
Kokash J; Alderson EM; Reinhard SM; Crawford CA; Binder DK; Ethell IM; Razak KA
Brain Res; 2019 Sep; 1719():24-29. PubMed ID: 31128097
[TBL] [Abstract][Full Text] [Related]
33. Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.
Wang X; Snape M; Klann E; Stone JG; Singh A; Petersen RB; Castellani RJ; Casadesus G; Smith MA; Zhu X
J Neurochem; 2012 May; 121(4):672-9. PubMed ID: 22393900
[TBL] [Abstract][Full Text] [Related]
34. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
[TBL] [Abstract][Full Text] [Related]
35. BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse.
Louhivuori V; Vicario A; Uutela M; Rantamäki T; Louhivuori LM; Castrén E; Tongiorgi E; Akerman KE; Castrén ML
Neurobiol Dis; 2011 Feb; 41(2):469-80. PubMed ID: 21047554
[TBL] [Abstract][Full Text] [Related]
36. Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9.
Toledo MA; Wen TH; Binder DK; Ethell IM; Razak KA
Behav Brain Res; 2019 Oct; 372():112068. PubMed ID: 31271818
[TBL] [Abstract][Full Text] [Related]
37. Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes.
Musumeci SA; Calabrese G; Bonaccorso CM; D'Antoni S; Brouwer JR; Bakker CE; Elia M; Ferri R; Nelson DL; Oostra BA; Catania MV
Exp Neurol; 2007 Jan; 203(1):233-40. PubMed ID: 17007840
[TBL] [Abstract][Full Text] [Related]
38. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome.
Thomas AM; Bui N; Perkins JR; Yuva-Paylor LA; Paylor R
Psychopharmacology (Berl); 2012 Jan; 219(1):47-58. PubMed ID: 21656124
[TBL] [Abstract][Full Text] [Related]
39. Cochlear Nucleus Transcriptome of a Fragile X Mouse Model Reveals Candidate Genes for Hyperacusis.
Sakano H; Castle MS; Kundu P
Laryngoscope; 2024 Mar; 134(3):1363-1371. PubMed ID: 37551886
[TBL] [Abstract][Full Text] [Related]
40. Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins.
Spencer CM; Serysheva E; Yuva-Paylor LA; Oostra BA; Nelson DL; Paylor R
Hum Mol Genet; 2006 Jun; 15(12):1984-94. PubMed ID: 16675531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
